Entries by akiibdh

AM-Pharma announces positive results of Phase IIa clinical trial with Alkaline Phosphatase for ulcerative colitis

Bunnik, The Netherlands, 9 July 2007. AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, today announced the positive clinical results of its Phase IIa Alkaline Phosphatase (AP) trial for patients with ulcerative colitis, a chronic and relapsing inflammatory bowel disease affecting the colon. In this recent trial, AP was […]

AM-Pharma announces positive results of a Phase IIa clinical trial with Alkaline Phosphatase in Acute Kidney Injury

Bunnik, The Netherlands, 12 March, 2007. AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, today announced positive results in patients with Acute Renal Failure. The patients involved were a subgroup of a Phase IIa trial with Alkaline Phosphatase to treat Sepsis. Plasma creatinine clearance, a marker for renal function, […]

AM-Pharma announces the appointment of Bart Wuurman as CEO

Bart Wuurman, M. Sc. replaces Bruno Giannetti, MD., Ph.D., who left AM-Pharma in December 2006. Bart Wuurman has 18 years of International Pharma and Biotechnology Industry experience with Organon, Medeva and Antisoma, where he was responsible for a $500 million oncology alliance with Roche. In 2003 Bart became CEO of De Novo Pharmaceuticals in Cambridge, […]

Dutch Biopharmaceutical Company AM-Pharma announces positive results in its double-blind, placebo controlled Phase IIa Sepsis trial with Alkaline Phosphatase

Bunnik, the Netherlands, 20 October 2006. AM-Pharma B.V., a biopharmaceutical company engaged in the pre-clinical and early clinical development of novel compounds to treat infectious and inflammatory diseases, announces first positive results observed in its multi-center double blind, placebo-controlled pilot study in the treatment of sepsis with its patented Alkaline Phosphatase (AP) drug. The study […]